18560003. STRUCTURE BASED ISOLATION OF PMHC-RESTRICTED ANTIBODIES simplified abstract (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY)

STRUCTURE BASED ISOLATION OF PMHC-RESTRICTED ANTIBODIES

Organization Name

THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Inventor(s)

Kenan Christopher Garcia of Menlo Park CA (US)

Daisuke Nishimiya of Redwood City CA (US)

Xinbo Yang of Palo Alto CA (US)

STRUCTURE BASED ISOLATION OF PMHC-RESTRICTED ANTIBODIES - A simplified explanation of the abstract

This abstract first appeared for US patent application 18560003 titled 'STRUCTURE BASED ISOLATION OF PMHC-RESTRICTED ANTIBODIES

• • Simplified Explanation:**

The patent application describes the development and screening of antibody-based binding regions that mimic T cell receptor specificity.

• • Key Features and Innovation:**
• Development of TCRm-ABR that specifically bind to the combination of an MHC antigen and peptide.
• Substantial lack of binding to the MHC in the absence of the cognate antigen.

• • Potential Applications:**

This technology could be used in the development of novel therapeutic antibodies for targeting specific antigens in diseases such as cancer and autoimmune disorders.

• • Problems Solved:**

This technology addresses the need for more precise and targeted antibody therapies by mimicking the specificity of T cell receptors.

• • Benefits:**
• Enhanced specificity in targeting antigens.
• Potential for improved efficacy and reduced side effects in antibody-based therapies.

• • Commercial Applications:**

The technology could have significant commercial applications in the biopharmaceutical industry for the development of new antibody-based drugs targeting specific antigens.

• • Questions about Antibody-Based Binding Regions:**

1. How do TCRm-ABRs differ from traditional antibodies in terms of specificity and binding capabilities? 2. What potential impact could TCRm-ABRs have on the field of immunotherapy for cancer and autoimmune diseases?

• • Frequently Updated Research:**

Researchers are continually exploring new ways to optimize the design and functionality of TCRm-ABRs for improved therapeutic applications.

Original Abstract Submitted

Compositions and methods are provided for the development and screening of antibody-based binding regions (ABR) that mimic T cell receptor specificity (TCRm). The TCRm-ABR of the disclosure are developed to specifically bind to the combination of an MHC antigen and peptide, and to substantially lack binding to the MHC in the absence of the cognate antigen.